AN2 Therapeutics Inc ANTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
AN2 Therapeutics to Present at Jefferies Global Healthcare Conference in London
AN2 Therapeutics Advances Pipeline With Development Candidate Nomination for Hypophosphatasia (HPP)
AN2 Therapeutics Receives U.S. FDA IND Clearance to Proceed with Planned Phase 2 Global Study of Oral Epetraborole in Polycythemia Vera
AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4)
AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms
AN2 Therapeutics to Participate at Upcoming Investor Conferences
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of AN2 Therapeutics, Inc. (NASDAQ: ANTX)
AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK
Trading Information
- Previous Close Price
- $3.96
- Day Range
- $4.06–4.06
- 52-Week Range
- $1.00–7.19
- Bid/Ask
- $3.90 / $4.21
- Shares Outstanding
- 37.74M
- Market Cap
- $150.57M
- Volume/Avg
- 168 / 259,951
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 21
Valuation
Metric | ANTX |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.89 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | ANTX |
|---|---|
Quick Ratio | 14.04 |
Current Ratio | 14.32 |
Interest Coverage | — |
Quick Ratio
ANTX
Profitability
Metric | ANTX |
|---|---|
Return on Assets (Normalized) | −42.28% |
Return on Equity (Normalized) | −46.54% |
Return on Invested Capital (Normalized) | −50.27% |
Return on Assets
ANTX
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|k@&F@^ | LOCK|ZDb$ | $138B | |||
| Moderna Inc MRNA | LOCK|z<$G$k | LOCK|^@ | $96B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|pBxVVJ | LOCK|>!cb | $93B | |||
| argenx SE ADR ARGX | LOCK|<#^W!& | LOCK|cn | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|>NcrPw | LOCK|DKM | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|PN<LP>% | LOCK|jR%d | $30B | |||
| Incyte Corp INCY | LOCK|Xpmw^M | LOCK|hkB | $24B | |||
| BioNTech SE ADR BNTX | LOCK|Kv#&FV | LOCK|?b | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|<>j^%!m | LOCK|z@vX^ | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|!Sn?<L | LOCK|#N | $15B |
United States